Expand DVAX Menu
DVAX MENU

DVAX Latest Press Releases

-- February 4, 2026 --

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 PRNewswire 6:15 PM

-- January 6, 2026 --

Halper Sadeh LLC Encourages DVAX, FONR, DBRG, ONTF Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 3:01 PM

-- January 5, 2026 --

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX) PRNewswire 2:22 PM

-- December 30, 2025 --

Halper Sadeh LLC Encourages DVAX, CWAN, DBRG Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 10:20 AM

-- December 29, 2025 --

Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX Business Wire 6:37 PM
Shareholder Alert: The Ademi Firm investigates whether DigitalBridge Group, Inc. is obtaining a Fair Price for its Public Shareholders PRNewswire 12:00 PM

-- December 24, 2025 --

Shareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public Shareholders PRNewswire 11:30 AM
DVAX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Dynavax Technologies Corporation is Fair to Shareholders Business Wire 5:31 AM
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline PRNewswire 1:24 AM

-- November 19, 2025 --

Dynavax to Participate at the 8th Annual Evercore Healthcare Conference PRNewswire 4:01 PM

-- November 5, 2025 --

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program PRNewswire 4:01 PM
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program PRNewswire 4:00 PM

-- October 22, 2025 --

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 PRNewswire 4:01 PM

-- October 21, 2025 --

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial PRNewswire 4:01 PM
Market Data Delayed 15 Minutes